Researchers have developed a therapy to treat Stargardt disease, the most common form of inherited macular degeneration, which often leads to vision loss. Their study shows promising results using a ...

Gene editing technique developed in Switzerland shows promise in curing Stargardt disease, a rare genetic eye disease causing ...

Benchmark analysts have increased the price target for Belite Bio, Inc (NASDAQ:BLTE) shares to $79.00, up from the previous ...

The adenine base editor corrected the most common mutation associated with Stargardt disease in the ABCA4 gene with no ...

Belite Bio, Inc (NASDAQ:BLTE – Get Free Report) gapped up prior to trading on Wednesday after Benchmark raised their price ...

Back to Healio Healio’s top FDA articles in ophthalmology this year included updates on the Vabsymo prefilled syringe, two new aflibercept biosimilars and an oral therapy for Stargardt disease.

Benchmark raised the firm’s price target on Belite Bio (BLTE) to $79 from $57 and keeps a Buy rating on the shares. After speaking to ...